<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04313166</url>
  </required_header>
  <id_info>
    <org_study_id>CMD-2020-001</org_study_id>
    <nct_id>NCT04313166</nct_id>
  </id_info>
  <brief_title>Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001</brief_title>
  <official_title>A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Complete Study CMD-2019-001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collaborative Medicinal Development Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Collaborative Medicinal Development Pty Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Provides up to six months treatment with CuATSM for subjects who have successfully completed
      study CMD-2019-001
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Provides up to six months treatment with CuATSM for subjects who have successffulyl completed
      study CMD-2019-001. [This allows subjects randomized to placebo on study CMD-2019-001 to
      receive up to six months treatment with CuATSM and provides an up to an additional six months
      treatment with CuATSM for subjects randomized to CuATSM on study CMD-2019-001]
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 19, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related changes in disease severity</measure>
    <time_frame>24 weeks</time_frame>
    <description>Treatment-related changes in disease severity assessed by ALS Functional Rating Scale - Revised (ALSFRS-R)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related changes in cognitive function</measure>
    <time_frame>24 weeks</time_frame>
    <description>Treatment-related changes in cognitive function by Edinburgh Cognitive and Behavioral Assessment (ECAS) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related changed in respiratory function</measure>
    <time_frame>SVC</time_frame>
    <description>Treatment-related changes in respiratory function by seated slow vital capacity (SVC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment tolerance</measure>
    <time_frame>24 weeks</time_frame>
    <description>Treatment tolerance based on dose reductions and dose terminations due to adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cu(II)ATSM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>copper-containing synthetic small molecule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cu(II)ATSM</intervention_name>
    <description>cooper-containing synthetic small molecule</description>
    <arm_group_label>Cu(II)ATSM</arm_group_label>
    <other_name>diacetylbis(N(4)-methylthiosemicarbazonato) copper(II)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent prior to initiation of any study-specific procedures and
             treatment

          -  documented completion of protocol-specified assessments following completion of 24
             weeks treatment on study CMD-2019-002

          -  Investigator considers patient has been tolerating treatment on study CMD-2019-001 and
             may benefit from continued treatment with CuATSM

        Exclusion Criteria:

          -  not dependent on mechanical ventilation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominic Rowe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Macquarie University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kay Noel, PhD</last_name>
    <phone>5108152575</phone>
    <email>kay.noel@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Macquarie University</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominic Rowe, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 15, 2020</study_first_submitted>
  <study_first_submitted_qc>March 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 15, 2020</last_update_submitted>
  <last_update_submitted_qc>March 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

